The findings of the current study are further supported by reports that dapagliflozin use may inhibit the fructose-induced superoxide generation caused by RAGE-mediated NADPH oxidase activation, thereby preventing cataract development in patients with diabetes. Here, FMO5 is linked to diabetes mellitus.